Physician profile
John D Belknap
NPI 1124180567
$705.89
in general payments reported to CMS, 2019-2025
12 companies · $76.36 in 2025
The $76.36 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $402 · 2022: $71.41 · 2023: $40.39 · 2024: $116 · 2025: $76.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $367.60 | 2021 | |
| Janssen Pharmaceuticals, INC | $71.41 | 2022 | |
| Novo Nordisk INC | $69.54 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $37.85 | 2025 | |
| Pfizer INC. | $33.65 | 2024-2025 | |
| Inari Medical, INC. | $27.04 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $22.50 | 2023 | Dificid |
| Xeris Pharmaceuticals, INC. | $18.28 | 2021 | |
| Glaxosmithkline, LLC. | $17.89 | 2023 | Arexvy |
| Medtronic, INC. | $13.77 | 2024 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.28 | 2024 | Caplyta |
| Exact Sciences Corporation | $13.08 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Belknap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.